Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

Study Overview
=================
Brief Summary
-----------------
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions. Partly it is due to the limited efficacy and safety problems of existing pharmacotherapy. Only one drug, orlistat, is approved for long-term use in obesity; but its effects on weight are relatively small. There are drugs that have been approved for other diseases but which also reduce weight. One promising approach to treating obesity is combination therapy with orlistat and one or more of these other agents. The investigators propose an innovative approach to developing new therapies for obesity coupling the use of combination therapy with rigorous assessment of cardiovascular safety. Vascular function is a quantitative surrogate clinical endpoint that has been strongly and independently linked to future cardiovascular events. Our hypothesis is that combination pharmacotherapy will reduce weight and improve vascular function in obese human subjects. The co-primary endpoints will be weight and vascular function.

Official Title
-----------------
Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?

Conditions
-----------------
Obesity, Metabolic Syndrome X

Intervention / Treatment
-----------------
* Drug: Metformin
* Drug: Orlistat
* Drug: Topiramate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 40 to 75 years Male or postmenopausal female BMI ≥ 30 kg/m2 One or more major cardiovascular (CV) risk factors (hypertension, dyslipidemia, impaired glucose tolerance OR metabolic syndrome) Exclusion Criteria: Congestive heart failure Renal impairment History of bariatric surgery (i.e. lap-band, Roux-en-Y or biliopancreatic diversion) Type I diabetes mellitus Weight loss > 10% in the past 6 months Recurrent nephrolithiasis Current treatment for seizure disorder Hepatic cirrhosis Current use of study medications Current use of oral estrogen History of smoking cessation in the past three months Current cholestasis or malabsorption syndrome Planned use of any herbal or over-the-counter supplements for weight loss History of allergic reactions to metformin, topiramate, orlistat or any of ingredients Medical conditions requiring continuous use of phosphodiesterase inhibitors and/or the inability to withhold phosphodiesterase inhibitors for 48 hours Participation in another clinical drug study within four weeks prior to this investigation. Participation in any other weight loss or rigorous exercise program. Any disease or condition that in the opinion of the investigator may interfere with completion of the study

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Metformin<br> | Drug: Metformin<br> <br> |
| Experimental: Metformin + Orlistat<br> | Drug: Metformin<br> <br> Drug: Orlistat<br> <br> |
| Experimental: Metformin + Topiramate<br> | Drug: Metformin<br> <br> Drug: Topiramate<br> <br> |
| Experimental: Topiramate<br> | Drug: Topiramate<br> <br> |
| Experimental: Metformin + Topiramate + Orlistat<br> | Drug: Metformin<br> <br> Drug: Orlistat<br> <br> Drug: Topiramate<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo pills and capsules for metformin, orlistat and topiramate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight (% Change From Baseline) | Weight obtained in the fasting state on a gowned subject. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Office Systolic Blood Pressure (mmHg Change From Baseline) | Automated sphygmomanometry while sitting | 6 months | 
| Waist (cm Change After 6 Months From Baseline) | Body fat distribution measured using anthropometry (waist, neck and hip circumferences) | 6 months | 
| Carotid-femoral Pulse Wave Velocity (PWV)(Change After 6 Months From Baseline) | Change in carotid-femoral pulse wave velocity (Sphygmocor). | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Metabolic Syndrome X, Hypertension, Dyslipidemia, Impaired glucose tolerance